vs

Side-by-side financial comparison of NEOGENOMICS INC (NEO) and OCTAVE SPECIALTY GROUP INC (OSG). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $104.2M, roughly 1.8× OCTAVE SPECIALTY GROUP INC). OCTAVE SPECIALTY GROUP INC runs the higher net margin — -6.6% vs -57.9%, a 51.3% gap on every dollar of revenue. On growth, OCTAVE SPECIALTY GROUP INC posted the faster year-over-year revenue change (66.0% vs 11.1%). Over the past eight quarters, OCTAVE SPECIALTY GROUP INC's revenue compounded faster (42.9% CAGR vs 6.5%).

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

Octave Specialty Group Inc. is a specialty insurance holding company that provides tailored property and casualty insurance products. Its core business focuses on excess and surplus lines, catering to commercial and individual clients across primary North American markets with customized risk coverage solutions.

NEO vs OSG — Head-to-Head

Bigger by revenue
NEO
NEO
1.8× larger
NEO
$186.7M
$104.2M
OSG
Growing faster (revenue YoY)
OSG
OSG
+54.9% gap
OSG
66.0%
11.1%
NEO
Higher net margin
OSG
OSG
51.3% more per $
OSG
-6.6%
-57.9%
NEO
Faster 2-yr revenue CAGR
OSG
OSG
Annualised
OSG
42.9%
6.5%
NEO

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
NEO
NEO
OSG
OSG
Revenue
$186.7M
$104.2M
Net Profit
$-108.0M
$-6.9M
Gross Margin
43.3%
Operating Margin
46.9%
Net Margin
-57.9%
-6.6%
Revenue YoY
11.1%
66.0%
Net Profit YoY
42.0%
EPS (diluted)
$-0.13
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEO
NEO
OSG
OSG
Q1 26
$186.7M
$104.2M
Q4 25
$190.2M
$66.9M
Q3 25
$187.8M
$66.6M
Q2 25
$181.3M
$55.0M
Q1 25
$168.0M
$62.8M
Q4 24
$172.0M
$65.2M
Q3 24
$167.8M
$70.0M
Q2 24
$164.5M
$51.0M
Net Profit
NEO
NEO
OSG
OSG
Q1 26
$-108.0M
$-6.9M
Q4 25
$-29.7M
Q3 25
$-27.1M
$-112.6M
Q2 25
$-45.1M
$-72.7M
Q1 25
$-25.9M
$-44.7M
Q4 24
$-20.9M
Q3 24
$-17.7M
$-27.5M
Q2 24
$-18.6M
$-750.0K
Gross Margin
NEO
NEO
OSG
OSG
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
NEO
NEO
OSG
OSG
Q1 26
46.9%
Q4 25
-7.1%
-76.7%
Q3 25
-14.4%
-48.2%
Q2 25
-26.3%
-41.8%
Q1 25
-16.6%
-24.1%
Q4 24
-10.7%
-55.5%
Q3 24
-12.6%
-29.7%
Q2 24
-13.3%
-28.9%
Net Margin
NEO
NEO
OSG
OSG
Q1 26
-57.9%
-6.6%
Q4 25
-73.8%
Q3 25
-14.4%
-169.1%
Q2 25
-24.9%
-132.3%
Q1 25
-15.4%
-71.3%
Q4 24
-55.1%
Q3 24
-10.5%
-39.3%
Q2 24
-11.3%
-1.5%
EPS (diluted)
NEO
NEO
OSG
OSG
Q1 26
$-0.13
$-0.13
Q4 25
$-0.82
Q3 25
$-2.35
Q2 25
$-1.54
Q1 25
$-1.22
Q4 24
$-11.75
Q3 24
$-0.63
Q2 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEO
NEO
OSG
OSG
Cash + ST InvestmentsLiquidity on hand
$146.1M
Total DebtLower is stronger
$117.1M
Stockholders' EquityBook value
$828.8M
$833.6M
Total Assets
$1.3B
$2.3B
Debt / EquityLower = less leverage
0.14×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEO
NEO
OSG
OSG
Q1 26
$146.1M
Q4 25
$159.6M
$146.4M
Q3 25
$164.1M
$27.5M
Q2 25
$154.7M
$22.5M
Q1 25
$346.2M
$34.1M
Q4 24
$367.0M
$157.2M
Q3 24
$362.0M
$40.8M
Q2 24
$355.1M
$14.6M
Total Debt
NEO
NEO
OSG
OSG
Q1 26
$117.1M
Q4 25
$341.9M
$117.6M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
$0
Q3 24
$518.0M
Q2 24
$515.0M
Stockholders' Equity
NEO
NEO
OSG
OSG
Q1 26
$828.8M
$833.6M
Q4 25
$836.6M
$715.8M
Q3 25
$838.3M
$843.4M
Q2 25
$854.0M
$859.8M
Q1 25
$888.3M
$852.2M
Q4 24
$902.3M
$798.4M
Q3 24
$908.2M
$1.5B
Q2 24
$915.9M
$1.4B
Total Assets
NEO
NEO
OSG
OSG
Q1 26
$1.3B
$2.3B
Q4 25
$1.4B
$2.2B
Q3 25
$1.4B
$2.1B
Q2 25
$1.4B
$8.5B
Q1 25
$1.6B
$8.3B
Q4 24
$1.6B
$8.1B
Q3 24
$1.6B
$9.3B
Q2 24
$1.6B
$8.2B
Debt / Equity
NEO
NEO
OSG
OSG
Q1 26
0.14×
Q4 25
0.41×
0.16×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
0.00×
Q3 24
0.35×
Q2 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEO
NEO
OSG
OSG
Operating Cash FlowLast quarter
$-8.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEO
NEO
OSG
OSG
Q1 26
$-8.1M
Q4 25
$1.3M
$-52.3M
Q3 25
$8.9M
$-41.2M
Q2 25
$20.3M
$2.1M
Q1 25
$-25.3M
$-12.6M
Q4 24
$9.8M
$762.0K
Q3 24
$9.2M
$48.9M
Q2 24
$13.9M
$20.4M
Free Cash Flow
NEO
NEO
OSG
OSG
Q1 26
Q4 25
$-6.5M
Q3 25
$570.0K
Q2 25
$14.0M
Q1 25
$-29.8M
Q4 24
$-1.8M
Q3 24
$-1.6M
Q2 24
$814.0K
FCF Margin
NEO
NEO
OSG
OSG
Q1 26
Q4 25
-3.4%
Q3 25
0.3%
Q2 25
7.7%
Q1 25
-17.8%
Q4 24
-1.0%
Q3 24
-0.9%
Q2 24
0.5%
Capex Intensity
NEO
NEO
OSG
OSG
Q1 26
Q4 25
4.1%
Q3 25
4.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
6.7%
Q3 24
6.4%
Q2 24
8.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEO
NEO

Segment breakdown not available.

OSG
OSG

Commissions$68.2M65%
Other$20.6M20%
Servicing and other fees$9.4M9%
Program fees$3.6M3%
Investment income$2.4M2%

Related Comparisons